Half‐Life Extension of the IgG‐Degrading Enzyme (IdeS) Using Fc‐Fusion Technology
European Journal of Immunology · 2025
DOI: 10.1002/eji.202451264 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2025. Verfasst von Victoria Daventure und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, CNRS, Sorbonne Université, Université Paris Cité, Pari…. Hauptthemen laut MEDLINE: Immunoglobulin G, Immunoglobulin Fc Fragments, Recombinant Fusion Proteins, Bacterial Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Spark Therapeutics Inc. (Philadelphia, PA).
Abstract (Originalsprache)
Imlifidase (IdeS) is a bacterial protease that hydrolyzes human IgG in their hinge region, decreasing their half‐life and abrogating their Fc‐mediated properties. It is now successfully used in therapy to prevent graft rejection during kidney transplants and is being clinically evaluated in several IgG‐mediated autoimmune diseases. IdeS short half‐life however limits its clinical use, particularly in the case of chronic diseases that would request repeated administrations. Here, we developed IdeS‐Fc fusion proteins as a divalent homodimer (IdeS‐Fc div ) or a monovalent heterodimer (IdeS‐Fc monov ), in order to extend the IgG‐depleting action of IdeS over time. Both IdeS‐Fc efficiently separated monoclonal and polyclonal human IgG into F(ab') 2 and Fc fragments, although with slower kinetics than their native counterpart. IdeS‐Fc monov exhibited a seven‐fold half‐life extension in vivo as compared with IdeS, and a significantly better residual cleavage of human IgG at later time points after injection. Our results provide proof of concept for the use of an IdeS with extended IgG‐hydrolyzing functions in vivo that could rapidly translate to the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, CNRS, Sorbonne Université, Université Paris Cité, Paris, France.
ORCID-Profile: Alejandra Reyes-Ruiz, Claire Deligne
Förderung
- Institut National de la Santé et de la Recherche Médicale
- Centre National de la Recherche Scientifique
- Spark Therapeutics Inc. (Philadelphia, PA)
- Innovative Medicines Initiative 2 Joint Undertaking ARDAT
- Accelerating research & development for advanced therapies
- MHEMO
- Sorbonne Université, Université Paris Cité
- Filière des maladies hémorragiques constitutionnelles
Zitieren
APA
Daventure, V., Bou-Jaoudeh, M., Hannachi, E., Reyes-Ruiz, A., Trecco, A., Delignat, S., Lacroix-Desmazes, S., & Deligne, C. (2025). Half‐Life Extension of the IgG‐Degrading Enzyme (IdeS) Using Fc‐Fusion Technology. European Journal of Immunology. https://doi.org/10.1002/eji.202451264
Vancouver
Daventure V, Bou-Jaoudeh M, Hannachi E, Reyes-Ruiz A, Trecco A, Delignat S, et al. Half‐Life Extension of the IgG‐Degrading Enzyme (IdeS) Using Fc‐Fusion Technology. European Journal of Immunology. 2025. doi:10.1002/eji.202451264
BibTeX
@article{Daventure2025,
author = {Daventure, Victoria and Bou-Jaoudeh, Melissa and Hannachi, Emna and Reyes-Ruiz, Alejandra and Trecco, Amélia and Delignat, Sandrine and Lacroix-Desmazes, Sébastien and Deligne, Claire},
title = {Half‐Life Extension of the IgG‐Degrading Enzyme (IdeS) Using Fc‐Fusion Technology},
journal = {European Journal of Immunology},
year = {2025},
doi = {10.1002/eji.202451264}
}
EUVIMED